COVID-19 in Northeast Bosnia and Herzegovina and patient's length of hospitalization.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
19 Apr 2021
Historique:
received: 02 06 2020
accepted: 05 04 2021
entrez: 20 4 2021
pubmed: 21 4 2021
medline: 23 4 2021
Statut: epublish

Résumé

Since the outbreak of COVID-19 pandemic, clinical data from various parts of the world have been reported. Up till now, there has been no clinical data with regards to COVID-19 from Bosnia and Herzegovina (B&H). The aim was to report on the first cohort of patients from B&H and to analyze factors that influence COVID-19 patient's length of hospitalization (LOH). This retrospective cohort study was conducted at Tuzla University Clinical Center (UKC), B&H. It involved 25 COVID-19 positive patients that needed hospitalisation between March 28th and April 27th 2020. The LOH was measured from the time of admission to discharge. Factors analyzed induced age, BMI, presence of known comorbidities, serum creatinine and O The mean age was 52.92 ± 19.15 years and BMI 28.80 ± 4.22. LOH for patients with BMI < 25 was 9 ± SE2.646 days (CI 95% 3.814-14.816) vs 14.182 ± SE .937 (CI 95% 12.346-16.018 p < 0.05; HR 5.148 CI95% 1.217 to 21.772 p = 0.026) for ≥25 BMI. The mean LOH of patients with normal levels of O LOH varied among COVID-19 patients and was prolonged when analyzed for BMI ≥25, comorbidities, elevated creatinine, and O2 saturation < 95%. Furthermore, risk factors for COVID-19 patients in B&H do not deviate from those reported in other countries.

Sections du résumé

BACKGROUND BACKGROUND
Since the outbreak of COVID-19 pandemic, clinical data from various parts of the world have been reported. Up till now, there has been no clinical data with regards to COVID-19 from Bosnia and Herzegovina (B&H). The aim was to report on the first cohort of patients from B&H and to analyze factors that influence COVID-19 patient's length of hospitalization (LOH).
METHODS METHODS
This retrospective cohort study was conducted at Tuzla University Clinical Center (UKC), B&H. It involved 25 COVID-19 positive patients that needed hospitalisation between March 28th and April 27th 2020. The LOH was measured from the time of admission to discharge. Factors analyzed induced age, BMI, presence of known comorbidities, serum creatinine and O
RESULTS RESULTS
The mean age was 52.92 ± 19.15 years and BMI 28.80 ± 4.22. LOH for patients with BMI < 25 was 9 ± SE2.646 days (CI 95% 3.814-14.816) vs 14.182 ± SE .937 (CI 95% 12.346-16.018 p < 0.05; HR 5.148 CI95% 1.217 to 21.772 p = 0.026) for ≥25 BMI. The mean LOH of patients with normal levels of O
CONCLUSION CONCLUSIONS
LOH varied among COVID-19 patients and was prolonged when analyzed for BMI ≥25, comorbidities, elevated creatinine, and O2 saturation < 95%. Furthermore, risk factors for COVID-19 patients in B&H do not deviate from those reported in other countries.

Identifiants

pubmed: 33874896
doi: 10.1186/s12879-021-06034-6
pii: 10.1186/s12879-021-06034-6
pmc: PMC8054235
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

367

Références

Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
Crit Rev Microbiol. 2020 Mar;46(2):182-193
pubmed: 32282268
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Infect Genet Evol. 2020 Sep;83:104327
pubmed: 32320825
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Am J Physiol Regul Integr Comp Physiol. 2018 Nov 1;315(5):R895-R906
pubmed: 30088946
Int J Antimicrob Agents. 2020 Jun;55(6):105948
pubmed: 32201353
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Pediatrics. 2016 Jul;138(1):
pubmed: 27343232
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
J Comput Assist Tomogr. 2020 Sep/Oct;44(5):656-666
pubmed: 32842067
JAMA. 2009 Nov 4;302(17):1880-7
pubmed: 19822626
PLoS One. 2014 Mar 06;9(3):e89697
pubmed: 24603885

Auteurs

Alma Trnacevic (A)

Department of Infectious Diseases, Tuzla University Clinical Center, Ibre Pasica bb, 7500, Tuzla, Bosnia and Herzegovina.

Amer Mujkanovic (A)

Department of Infectious Diseases, Tuzla University Clinical Center, Ibre Pasica bb, 7500, Tuzla, Bosnia and Herzegovina. Amer.mujkanovic.18@ucl.ac.uk.

Noura Al-Salloum (N)

Department for Family Medicine, King Fahad Medical City, As Sulimaniyah, Riyadh, 12231, Saudi Arabia.

Amra Sakusic (A)

Mayo Clinic Florida; Mid Cheshire Hospitals NHS Foundation Trust, Middlewich Rd, Crewe, CW1 4QJ, UK.

Emir Trnacevic (E)

Department of Infectious Diseases, Tuzla University Clinical Center, Ibre Pasica bb, 7500, Tuzla, Bosnia and Herzegovina.

Emir Jusufovic (E)

Department of Infectious Diseases, Tuzla University Clinical Center, Ibre Pasica bb, 7500, Tuzla, Bosnia and Herzegovina.

Fatima Hukic (F)

Department of Infectious Diseases, Tuzla University Clinical Center, Ibre Pasica bb, 7500, Tuzla, Bosnia and Herzegovina.

Rahima Jahic (R)

Department of Infectious Diseases, Tuzla University Clinical Center, Ibre Pasica bb, 7500, Tuzla, Bosnia and Herzegovina.

Richard Stratton (R)

Department of Medicine, Royal Free Trust, Pond St, Hampstead, London, NW3 2QG, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH